Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer drops one weight loss drug, bets on another

By Brian Buntz | June 26, 2023

Pfizer logoPfizer has made a strategic decision in the battle against obesity and diabetes. The pharmaceutical giant has chosen to discontinue its GLP-1 RA candidate, lotiglipron, to focus resources on the development of another – danuglipron. This Pfizer weight loss drug is now the lead candidate in late-stage trials for the treatment of obesity and diabetes. The decision comes after the discovery of elevated liver enzyme levels in some early trial patients for lotiglipron. However, similar concerns have not arisen with danuglipron.

The shift comes as the company aims to tap full receptor agonism for potential robust efficacy, capitalizing on its small molecule design expertise. With more than 1,400 patients already enrolled, the clinical trial results could potentially expand the treatment options for adults with obesity and Type 2 diabetes.

Already, GLP drugs semaglutide and tirzapatide are beginning to reshape the way we treat obesity.

Novo Nordisk’s semaglutide, an existing GLP-1 RA, has shown strong results in controlling diabetes and enabling weight loss. Its long-acting formula, reduced impact on the liver, and weekly dosage have made it a leader in the treatment of obesity. Tirzapatide, another GLP-1 RA in clinical trials, could also revolutionize the treatment of obesity.

Lilly’s tirzepatide, the first dual GIP/GLP- coagonist, could hit $50 billion by 2030, according to analysts.

While competitors exist, GLP-1 RAs as a class offer diverse benefits that open up new possibilities for obesity therapies. These include increasing insulin, lowering glucagon, slowing digestion, increasing feelings of fullness, reducing appetite, and influencing immune cells.

Despite competitors, GLP-1 RAs could pave the way for new approaches to treating obesity. Semaglutide and tirzapatide, in particular, threaten to change how obesity is viewed and addressed. However, danuglipron, if successful, may distinguish itself through its potential for full receptor activation and strong results.

Pfizer aims to explore danuglipron’s potential for complete receptor activation and potent efficacy. The drug candidate has shown promising results in earlier trials, appearing to support dose-dependent weight loss and diabetes control. The side effect profile of danuglipron seemed similar to existing GLP-1 diabetes drugs.

Pfizer expects to finalize late-stage trial plans for danuglipron by year-end and is developing an extended-release version of the molecule.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE